Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

TRISTEL PLC Director's Dealing 2026

Mar 23, 2026

7990_dirs_2026-03-23_ad2d3e22-2086-44cd-ac66-8164703387c2.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 6737X

Tristel PLC

23 March 2026

A close-up of a logo Description automatically generated

Tristel plc

("Tristel" or the "Company")

Director/PDMR Shareholding

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it was notified on 20 March 2026 that Caroline Stephens, Non-Executive Director of the Company, purchased 2,597 ordinary shares of 1 penny each in the Company ("Ordinary Shares") at a price of 382.47 pence per Ordinary Share.

Following the purchase, Caroline Stephens' beneficial interest in the Company, including those held by her PCA, is 6,878 Ordinary Shares, representing approximately 0.014 per cent. of the Company's issued share capital.

For further information please contact:     

Tristel plc Via Walbrook PR
Matt Sassone, Chief Executive Officer www.investors.tristel.com
Anna Wasyl, Chief Financial Officer
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Paul McManus / Lianne Applegarth / Anna Dunphy Mob: 07980 541 893/ 07584 391 303/ 07876 741 001
Cavendish Capital Markets Ltd Tel: 020 7220 0500
Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance)
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

A blue and purple sign with white text AI-generated content may be incorrect.

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, which also encompasses its sporicidal surface disinfection range offered as a sustainable alternative to commonly used pre‑wetted plastic wipe.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets delivering double-digit revenue growth annually, an adjusted EBITDA margin of at least 25% and a continuing progressive year-on-year growth in dividends, underpinned by robust cash generation. 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: https://tristel.com 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Caroline Stephens

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tristel plc

b)

LEI

2138009DZ4LH9CZGF662

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 1p each in Tristel plc

GB00B07RVT99

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Price Volume
382.47 2,597

d)

Aggregated information

- Aggregated volume

- Price

2,597 Ordinary Shares of 1 penny each

382.47 pence

e)

Date of the transaction

20 March 2026

f)

Place of the transaction

London Stock Exchange (AIM)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDZGZFVFLGVZG